About
Sobi (Swedish Orphan Biovitrum AB) is a global biopharmaceutical company headquartered in Stockholm, Sweden, with a singular focus on rare diseases. Only 5% of the more than 10,000 identified rare diseases currently have approved medicines, making Sobi's mission both urgent and impactful for the 400 million people worldwide affected by these conditions. Sobi's therapeutic portfolio is concentrated in three primary areas: Haematology (including Haemophilia, Immune Thrombocytopenia, Paroxysmal Nocturnal Haemoglobinuria, and Diffuse Large B-Cell Lymphoma), Immunology (including Familial Mediterranean Fever and Cryopyrin-Associated Periodic Syndromes), and Specialty Care. The company pursues a robust R&D pipeline while also prioritising patient access through expanded access programmes, humanitarian aid, and clinical trials. Beyond drug development, Sobi is committed to sustainability — with validated science-based climate targets, increased renewable energy usage, and fossil-free vehicle fleets across multiple countries. Patient engagement is a core pillar: Sobi involves patients as equal contributors to decision-making, disease awareness, and value-added service design. The company also runs capability-building and trusted education initiatives for healthcare professionals and partners globally, making it a comprehensive rare disease ecosystem rather than simply a drug manufacturer.
Key Features
- Rare Disease Focus: Exclusively dedicated to developing and delivering therapies for rare diseases across Haematology, Immunology, and Specialty Care.
- Robust R&D Pipeline: Active pipeline of innovative medicines addressing conditions where fewer than 5% of rare diseases currently have approved treatments.
- Patient Access Programmes: Expanded access, humanitarian aid, and clinical trial programmes designed to bring treatments to patients globally, including underserved regions.
- Patient Engagement Model: Patients are involved as equal contributors across disease awareness, acquisitions, decision-making, and experience data collection.
- Sustainability Commitment: Science-based climate targets, renewable energy adoption, and fossil-free vehicle fleets underscore Sobi's environmental responsibility.
Use Cases
- Healthcare professionals seeking education and resources on rare haematological and immunological conditions treated by Sobi therapies.
- Patients and caregivers looking for information on rare disease diagnoses, available treatments, and access programmes.
- Investors and analysts monitoring Sobi's financial performance, pipeline progress, and strategic direction in the rare disease space.
- Partners and researchers interested in collaborating with Sobi on rare disease drug development, clinical trials, or humanitarian programmes.
- Policy and public health stakeholders exploring sustainable models for delivering rare disease care in underserved global markets.
Pros
- Specialised Rare Disease Expertise: Deep therapeutic focus means Sobi brings concentrated expertise and resources to conditions often overlooked by larger pharmaceutical companies.
- Global Patient Access Initiatives: Humanitarian programmes and expanded access schemes ensure that patients in low-resource settings can benefit from Sobi's therapies.
- Strong Pipeline Momentum: Consistent R&D investment and strategic partnerships drive a growing portfolio of innovative treatment options.
Cons
- Narrow Therapeutic Scope: Focus on rare diseases means Sobi's portfolio does not address common or widespread conditions, limiting broad market reach.
- Complex Regulatory Pathways: Rare disease drug development involves long timelines, high costs, and inherent risks due to small patient populations and limited clinical data.
Frequently Asked Questions
What diseases does Sobi focus on?
Sobi focuses on rare diseases primarily in three therapeutic areas: Haematology (Haemophilia, ITP, PNH, DLBCL), Immunology (FMF, CAPS), and Specialty Care.
How does Sobi support patient access to treatments?
Sobi runs expanded access programmes, humanitarian aid initiatives, and clinical trials to help patients globally — including in low-resource regions — gain access to its therapies.
Where is Sobi headquartered?
Sobi is headquartered in Stockholm, Sweden, at Norra Stationsgatan 93A, and operates globally.
Is Sobi a publicly traded company?
Yes, Sobi (Swedish Orphan Biovitrum AB) is a publicly traded biopharmaceutical company with regular financial reporting and investor relations activities.
What is Sobi's approach to sustainability?
Sobi has validated science-based climate targets, is increasing its use of renewable electricity, and is transitioning to fossil-free vehicle fleets across multiple countries.
